“Consistent with the EMERGENT-1 trial, EMERGENT-2 demonstrated statistically significant improvement in negative symptoms with KarXT compared with placebo based on changes from baseline to week 5,” the investigators wrote. “Together, these results support further testing of KarXT as a treatment for primary negative symptoms in an appropriately designed study in people with persistent negative symptoms, as the Marder negative factor might be less susceptible to influence by improvement in positive symptoms than the [Positive and Negative Syndrome Scale] negative subscale.”
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| If you’ve heard Cobenfy or karxt was only tested for 5 weeks | 0 | 136 | October 25, 2024 | |
| Karxt PANSS out again for Karuna; NDA slated for midyear | 17 | 900 | May 7, 2023 | |
| Will karXT improve negative symptoms? | 4 | 521 | July 24, 2023 | |
| Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study | 9 | 640 | December 10, 2022 | |
| Potential Impact of KarXT on Negative Symptoms in Acute Schizophrenia | 8 | 200 | July 25, 2024 |